- Dr Lee on Research Collaborations Studying PD-L1 as a Biomarker in NSCLCJonathan Wennan Lee, MD, MSc, discusses future directions for studying PD-L1 as a predictive biomarker in EGFR-mutated NSCLC.onclive · 2mo ago↗ source
- Dr Chari on Frontline Combinations and Transplant Approaches in Multiple MyelomaAjai Chari, MD, discusses frontline treatment and transplant considerations in multiple myeloma.onclive · 2mo ago↗ source
- FDA Accepts sNDA for Taletrectinib in ROS1+ NSCLCAn sNDA with updated data for taletrectinib was accepted by the FDA for TKI-naive and pretreated advanced ROS1+ NSCLConclive · 2mo ago↗ source